source
- Pfizer grants Medicus co-development rights to CD228-targeted ADC PF-08046031Pfizer announced it is transferring co-development rights for its CD228-targeted antibody-drug conjugate, PF-08046031, to Medicus Pharma. The ADC, originally discovered by Seagen, will now be adva…
- Novartis licenses Alteogen’s hyaluronidase enzyme ALT-B4 in new drug delivery partnershipNovartis announced a licensing agreement with South Korean biotech Alteogen to use its hyaluronidase enzyme ALT-B4 for drug delivery applications. The enzyme will be produced using Alteogen’s prop…